We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals

876 hedge funds and large institutions have $40B invested in Teva Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 290 increasing their positions, 310 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 135 | Existing positions closed: 69

79% more call options, than puts

Call options by funds: $1.18B | Put options by funds: $662M

50% more funds holding in top 10

Funds holding in top 10: 5887 (+29)

34% more capital invested

Capital invested by funds: $29.9B → $40B (+$10.1B)

6% more funds holding

Funds holding: 823876 (+53)

4.84% more ownership

Funds ownership: 55.28%60.12% (+4.8%)

6% less repeat investments, than reductions

Existing positions increased: 290 | Existing positions reduced: 310

Holders
876
Holders Change
+53
Holders Change %
+6.44%
% of All Funds
22.98%
Holding in Top 10
87
Holding in Top 10 Change
+29
Holding in Top 10 Change %
+50%
% of All Funds
2.28%
New
135
Increased
290
Reduced
310
Closed
69
Calls
$1.18B
Puts
$662M
Net Calls
+$522M
Net Calls Change
+$500M
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$320M +$57.3M +927,447 +23%
SIG
27
Senator Investment Group
New York
$312M +$77.2M +1,250,000 +36%
Janus Henderson Group
28
Janus Henderson Group
United Kingdom
$300M +$143M +2,312,491 +102%
EIP
29
Epoch Investment Partners
New York
$290M +$94.3M +1,525,374 +53%
First Eagle Investment Management
30
First Eagle Investment Management
New York
$287M -$5.9M -95,392 -2%
FTCM
31
Fir Tree Capital Management
New York
$280M -$26.3M -425,549 -9%
CI
32
Clal Insurance
Israel
$275M -$10.6M -171,256 -4%
BG
33
BlackRock Group
United Kingdom
$274M +$8.48M +137,154 +3%
MIFH
34
Migdal Insurance & Financial Holdings
Israel
$268M +$252M +4,082,699 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$263M -$25.9M -419,580 -9%
BRC
36
Blue Ridge Capital
New York
$263M +$247M +4,000,000 New
Westfield Capital Management
37
Westfield Capital Management
Massachusetts
$259M -$99.7M -1,613,980 -29%
Schroder Investment Management Group
38
Schroder Investment Management Group
United Kingdom
$251M +$149M +2,417,277 +172%
Boston Partners
39
Boston Partners
Massachusetts
$244M -$79.1M -1,279,172 -26%
BIM
40
BlackRock Investment Management
Delaware
$244M +$7.22M +116,913 +3%
ClearBridge Investments
41
ClearBridge Investments
New York
$242M +$3.2M +51,708 +1%
RFC
42
Russell Frank Company
Washington
$228M -$20.7M -335,419 -9%
JHIU
43
Janus Henderson Investors US
Colorado
$227M +$12.4M +200,003 +6%
Neuberger Berman Group
44
Neuberger Berman Group
New York
$225M -$12.2M -197,588 -5%
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$223M +$131M +2,112,174 +165%
Brown Advisory
46
Brown Advisory
Maryland
$212M +$8.7M +140,802 +5%
SC
47
Sculptor Capital
New York
$207M +$195M +3,157,639 New
Millennium Management
48
Millennium Management
New York
$197M +$61.2M +990,699 +49%
AllianceBernstein
49
AllianceBernstein
Tennessee
$195M -$14.3M -231,314 -7%
DCM
50
Discovery Capital Management
Connecticut
$194M +$183M +2,958,200 New

TEVA Hedge Fund Activity: Q4 2015 in Review

876 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2015, worth a combined $40B — up 34% from $29.9B a quarter earlier.

Buyers outnumbered sellers: 135 funds opened new TEVA positions and 69 closed out — a net gain of 66 holders — while 290 added to existing stakes and 310 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $999M. The largest seller was Franklin Resources, cutting an estimated $430M.

  • 876 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2015, up from 823 in Q3 2015.
  • Funds reported $40B of Teva Pharmaceuticals stock for Q4 2015, up 34% quarter-over-quarter.
  • 135 funds opened new Teva Pharmaceuticals positions in Q4 2015 and 69 closed out, a net change of +66 holders.
  • The largest Teva Pharmaceuticals buyer in Q4 2015 was Viking Global Investors, an estimated $999M added.
  • The largest Teva Pharmaceuticals seller in Q4 2015 was Franklin Resources, an estimated $430M sold.

Based on aggregated 13F filings for Q4 2015.